Related coverage linked through entity extraction aliases.
Apr 04, 2026
Large-cap healthcare stocks such as Johnson & Johnson and CVS Health are viewed as defensive in a slowdown, with beta values of 0.33 and 0.46. Investors can also pursue higher-risk healthcare companies such as Grail and Viking Therapeutics, whose performance depends more on clinical and product milestones.
Apr 02, 2026
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
Mar 17, 2026
ACT Capital Management invested $7.25 million in Viking Therapeutics as the company advances its obesity drug candidate VK2735 into Phase 3 trials. India's drug regulator warned pharmaceutical companies against direct or surrogate advertising of weight-loss medicines, while South Korean drugmakers target year-end commercialization of domestically developed obesity treatments.
Feb 18, 2026
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
Feb 18, 2026
European regulators approved a 7.2mg "megadose" of Novo Nordisk's Wegovy involving three weekly injections. The Danish drugmaker filed suit against Hims & Hers after the telehealth company briefly launched a compounded oral semaglutide product.
Feb 14, 2026
Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial for injectable VK2735 and plans to advance oral VK2735 into Phase 3, while also filing an IND for a new amylin agonist program targeting obesity.
Feb 13, 2026
Viking Therapeutics reported a full-year 2025 net loss of $359.64 million as it rapidly advanced its obesity candidate VK2735 into Phase 3 trials, with both injectable and oral formulations showing double-digit weight loss in earlier studies.
